Vertex Pharmaceuticals Price Prediction and Hype Density Breakdown

VRTX -- USA Stock  

Quarterly Earning Report: October 23, 2019  

We analyze noise-free headlines and recent hype associated with Vertex Pharmaceuticals Incorpor which may create opportunities for some arbitrage if properly timed. With Vertex Pharmaceuticals hype-based prediction module you can estimate the value of Vertex Pharmaceuticals Incorpor from the prospective of Vertex Pharmaceuticals response to recently generated media hype and the effects of current headlines on its competitors. The module also provides analysis of price elasticity to changes in media outlook on Vertex Pharmaceuticals over a specific investment horizon. Also please take a look at Vertex Pharmaceuticals Basic Forecasting Models to cross-verify your projections.
Horizon     30 Days    Login   to change

Vertex Pharmaceuticals After-Hype Price Density Analysis

 Next price density 
      Expected price to next headline 

Vertex Pharmaceuticals Estimiated After-Hype Price Volatility

October 16, 2019
Current Value
After-hype Price
Vertex Pharmaceuticals is very steady asset. Analysis and calculation of next after-hype price of Vertex Pharmaceuticals is based on 3 months time horizon.

Vertex Pharmaceuticals Next Price Analysis

Daily Expected returnPeriod VolatilityHype elasticityRelated hype elasticityAverage news densityRelated news densityNext Expected Hype
 0.00  1.77% 0.00   0.00  10 Events / Month3 Events / MonthIn about 10 days
Latest traded priceExpected after-news pricePotential return on next major newsAverage after-hype volatility

Vertex Pharmaceuticals Hype Timeline

Vertex Pharmaceuticals is at this time traded for172.41. The entity stock is not elastic to its hype. The average elasticity to hype of competition is 0.0. Vertex Pharmaceuticals Incorpor is projected to decline in value after the next headline with price expected to drop to 176.12. The average volatility of media hype impact on the company stock price is about 70.8%. The price decrease on the next news is expected to be -0.01% where as daily expected return is at this time at 0.0%. The volatility of related hype on Vertex Pharmaceuticals is about 710.84% with expected price after next announcement by competition of 172.41. About 97.0% of the company outstanding shares are owned by institutional investors. The company has Price/Earnings To Growth (PEG) ratio of 0.79. Vertex Pharmaceuticals recorded earning per share (EPS) of 8.52. The entity had not issued any dividends in recent years. The firm had 2:1 split on 2000-08-24. Given the investment horizon of 30 days, the next projected press release will be in about 10 days.
Also please take a look at Vertex Pharmaceuticals Basic Forecasting Models to cross-verify your projections.

Vertex Pharmaceuticals Related Hype Analysis

At Risk
Vertex Pharmaceuticals Incorpor(2.50) 10 per month 1.47  0.0153  2.26 (2.20)  11.20 
Dr Reddys Laboratories Ltd 0.27 6 per month 1.39  0.0262  2.22 (2.49)  7.44 
Sinovac Biotech Ltd 0.00 0 per month 0.00  0.00  0.00  0.00  0.00 
Zoetis 0.70 11 per month 1.30  0.14  2.32 (2.33)  10.51 
Immune Pharmaceuticals 0.00 0 per month 0.00  0.00  0.00  0.00  0.00 
Perrigo Company Plc(0.67) 5 per month 2.01  0.05  3.33 (2.93)  9.78 
PAREXEL International Corp 0.00 0 per month 0.00  0.00  0.00  0.00  0.00 
Regeneron Pharmaceuticals(0.80) 7 per month 1.83  0.0328  2.59 (2.96)  8.75 
SciClone Pharmaceuticals, In 0.00 0 per month 0.00  0.00  0.00  0.00  0.00 
Origin Agritech Limited 0.51 6 per month 2.89  0.0253  4.60 (5.19)  12.91 

Contributor Headline

Latest Prospective on Vertex Pharmaceuticals

Also please take a look at Vertex Pharmaceuticals Basic Forecasting Models to cross-verify your projections. Please also try Price Transformation module to use price transformation models to analyze depth of different equity instruments across global markets.